VistaGen Therapeutics Cash Flow from Financing

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

VistaGen Therapeutics's issuance of stock for the three months ended in Dec. 2021 was $0.17 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

VistaGen Therapeutics's repurchase of stock for the three months ended in Dec. 2021 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

VistaGen Therapeutics's net issuance of debt for the three months ended in Dec. 2021 was $-0.00 Mil. VistaGen Therapeutics spent $0.00 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

VistaGen Therapeutics's net issuance of preferred for the three months ended in Dec. 2021 was $0.00 Mil. VistaGen Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

VistaGen Therapeutics's cash flow for dividends for the three months ended in Dec. 2021 was $0.00 Mil. VistaGen Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

VistaGen Therapeutics's other financing for the three months ended in Dec. 2021 was $1.95 Mil. VistaGen Therapeutics received $1.95 Mil on other financial activities.

VistaGen Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.